

STRATEGIC PLANNING & INNOVATION

Results of Episodes of Care Program

CY 2015

\$10.8 million

- Providers and hospitals reduced costs while maintaining quality of care
- Gain sharing payments to providers exceeded risk sharing payments by \$280,000

CY 2016

\$14.5 million

- Quality metrics improved for perinatal, total joint replacement, and COPD, and were mostly maintained for the remaining episodes
- Gain sharing payments to providers exceeded risk sharing payments by \$395,000

CY 2017

\$28.6 million

- Quality metrics improved or maintained for most episodes
- Gain sharing payments to providers exceeded risk sharing payments by \$206,900

CY 2018

Estimated Savings*: \$38.3 million

- Quality metrics improved or maintained for most episodes
- Gain sharing payments to providers exceeded risk sharing payments by \$686,000

Episodes included: perinatal, total joint replacement (TJR), acute asthma exacerbation (asthma)

Episodes included: perinatal, TJR, asthma, colonoscopy, acute PCI, non-acute PCI, cholecystectomy, COPD

Episodes included: perinatal, TJR, asthma, colonoscopy, acute PCI, non-acute PCI, cholecystectomy (CHOLE), COPD, GI hemorrhage (GIH), EGD, respiratory infection (RI), pneumonia, UTI outpatient (UTI-O), UTI inpatient (UTI-I), CHF, ODD, CABG, valve, bariatric

Episodes included: perinatal, TJR, asthma, colonoscopy, acute PCI, non-acute PCI, CHOLE, COPD, GIH, EGD, RI, pneumonia, UTI-O, UTI-I, CHF, ODD, CABG, valve, bariatric, ADHD, breast biopsy, otitis media, tonsillectomy, SSTI, HIV, pancreatitis, and acute diabetes exacerbation



SAVINGS RESULTS

2018 Episodes Savings

Episodes estimated savings for 2018 is approximately **\$38.3 million** due to episodes' risk-adjusted cost being less than projected medical trend of a 3% annual increase

CY 2018 Episodes	Average Episode Spend (Projected)	Average Episode Spend (Actual)	Estimated Savings per Episode	Percent Savings per Episode	Number of Valid Episodes	Total Estimated Savings
Total	-	-	-	-	739,197	\$38,271,108
Perinatal	\$7,533	\$6,900	\$632	9.2%	21,283	\$13,456,251
Acute Asthma Exacerbation	\$1,326	\$951	\$375	39.4%	11,298	\$4,235,643
Total Joint Replacement	\$13,638	\$12,432	\$1,207	9.7%	419	\$505,532
Cholecystectomy	\$4,936	\$4,627	\$309	6.7%	1,828	\$565,725
Colonoscopy	\$1,180	\$995	\$184	18.5%	2,776	\$511,264
COPD	\$2,535	\$2,099	\$436	20.8%	3,916	\$1,706,887
Acute PCI	\$9,947	\$10,633	-\$686	-6.5%	376	-\$258,034
Non-acute PCI	\$7,348	\$7,430	-\$82	-1.1%	125	-\$10,253
GIH	\$3,781	\$3,933	-\$152	-3.9%	1,309	-\$198,963
EGD	\$1,284	\$1,163	\$121	10.4%	7,650	\$926,970
Respiratory Infection	\$128	\$112	\$16	14.4%	421,079	\$6,781,656
Pneumonia	\$1,298	\$1,240	\$57	4.6%	2,825	\$162,329
UTI-Outpatient	\$160	\$137	\$23	16.4%	36,927	\$834,223
UTI-Inpatient	\$4,329	\$3,673	\$656	17.9%	1,260	\$826,774
CHF	\$6,094	\$5,887	\$206	3.5%	2,251	\$464,635
ODD	\$1,405	\$1,042	\$363	34.9%	2,000	\$726,499
CABG	\$30,584	\$27,426	\$3,158	11.5%	172	\$543,118
Valve Repair and Replacement	\$74,825	\$49,478	\$25,347	51.2%	73	\$1,850,354
Bariatric Surgery	\$8,310	\$9,092	-\$782	-8.6%	644	-\$503,718
ADHD	\$1,326	\$1,285	\$41	3.2%	25,695	\$1,054,988
Breast Biopsy	\$1,783	\$1,701	\$82	4.8%	969	\$79,306
Otitis Media	\$162	\$149	\$13	8.5%	137,276	\$1,750,126
Tonsillectomy	\$2,721	\$2,565	\$156	6.1%	6,264	\$976,770
Skin and Soft Tissue Infection	\$225	\$204	\$21	10.4%	47,286	\$998,695
Pancreatitis	\$6,207	\$5,747	\$459	8.0%	707	\$324,700
Acute Diabetes Exacerbation	\$5,623	\$5,530	\$94	1.7%	891	\$83,371
HIV	\$1,014	\$1,079	-\$65	-6.0%	1,898	-\$123,740



QUALITY RESULTS

Wave 1 Episodes*	CY 2014	CY 2015	CY 2016	CY 2017	CY 2018	Target Performance	
Perinatal (21,283 valid ep	isodes)**						
1. HIV Screening (≥ 85%)	90.2%	88.3%	87.7%	89.1%	92.8%	1	
2. Group B Streptococcus						_	
Screening (≥ 85%)	87.8%	85.9%	94.0%	95.5%	95.2%	T	
3. C-Section Rate (≤ 41%)	30.5%	31.6%	30.6%	31.2%	30.8%	1	
Acute Asthma Exacerbation (11,298 valid episodes)							
1. Follow-up Visit with							
Physician (≥ 30%)	N/A	N/A***	29.6%	30.3%	32.4%	1	
2. Patient on Appropriate							
Medication (≥ 30%)	N/A	N/A***	60.3%	65.4%	69.5%	1	



^{*}There are no quality metrics tied to gain sharing for the total joint replacement episode

^{**}Valid episodes in 2018 performance period across all three MCOs

^{***}There was a coding change to these quality metrics so there is no direct comparison

					Target
Wave 2 Episodes*	CY 2015	CY 2016	CY 2017	CY 2018	Performance
Cholecystectomy (1,828 valid episo	des)**				
Hospitalization in Post-Trigger					_
Window (≤ 10%)	0.8%	1.0%	0.9%	0.3%	
COPD (3,916 valid episodes)					
 Follow-up Care Within Post- 					
Trigger Window (≥ 40%)	45.1%	46.7%	47.4%	46.7%	T
Acute PCI (376 valid episodes)					
Hospitalization in Post-Trigger					_
Window (≤ 10%)	1.0%	0.7%	0.7%	1.1%	1
Non-acute PCI (125 valid episodes)					
Hospitalization in Post-Trigger					
Window (≤ 10%)	0.0%	1.6%	0.0%	0.0%	1



^{*}There are no quality metrics tied to gain sharing for the colonoscopy episode

^{**}Valid episodes in 2018 performance period across all three MCOs

Wave 3 Episodes*	CY 2016	CY 2017	CY 2018	Target Performance
GI Hemorrhage (1,309 valid episodes)**				
1. Follow-up Care Within Post-Trigger Window				
<u>(</u> ≥ 40%)	49.0%	51.9%	50.1%	T
Pneumonia (2,825 valid episodes)				
1. Follow-up Care Within Post-Trigger Window				
<u>(</u> ≥ 30%)	N/A	N/A***	30.4%	T
UTI-Inpatient (1,260 valid episodes)				
1. Follow-up Care Within Post-Trigger Window				•
<u>(</u> ≥ 40%)	46.0%	43.5%	42.4%	
UTI-Outpatient (36,927 valid episodes)				
1. Admission Within the Trigger Window for ED				
Triggered Episodes (≤ 5%)****	5.6%	6.1%	7.0%	•
2. Admission Within the Trigger Window for				_
Non-ED Triggered Episodes (≤ 5%)****	0.8%	1.0%	1.0%	1

^{*}There are no quality metrics tied to gain sharing for the EGD and respiratory infection episode



^{**}Valid episodes in 2018 performance period across all three MCOs

^{***}There was a coding change to these quality metrics so there is no direct comparison

^{****}This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes.

Wave 4 Episodes	CY 2016	CY 2017	CY 2018	Target Performance
Bariatric Surgery (644 valid episodes)*				
1. Follow-up Care Within Post-Trigger Window (≥ 30%)	35.6%	37.4%	43.3%	1
CHF Acute Exacerbation (2,251 valid episodes)				
1. Follow-up Care Within Post-Trigger Window (≥ 60%)	56.2%	57.2%	57.0%	<u> </u>
ODD (2,000 valid episodes)				
1. Minimum Care Requirement (≥ 70%)	26.7%	35.8%	31.9%	<u> </u>
CABG (172 valid episodes)				
1. Follow-up Care Within Post-Trigger Window (≥ 90%)	71.4%	70.0%	78.5%	<u> </u>
Valve Repair and Replacement (73 valid episodes)				
1. Follow-up Care Within Post-Trigger Window (≥ 90%)	78.5%	77.7%	76.7%	1
ADHD (25,695 valid episodes)				
1. Minimum Care Requirement (≥ 70%)	N/A**	78.5%	78.8%	1
2. Long-acting Stimulants for Members Aged 6 to 11 Years (≥ 80%)***	N/A**	83.1%	82.9%	†
3. Long-acting Stimulants for Members Aged 12 to 20 Years (≥ 80%)***	N/A**	83.0%	83.1%	1
4. Utilization of Therapy for Members Aged 4 and 5 Years (1 visit)***	N/A**	1.42	1.71	1

^{*}Valid episodes in 2018 performance period across all three MCOs

^{***} This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes.



^{**}The preview period for the ADHD episode was 2017. The initial performance period for the ADHD episode was 2018

Wave 5 Episodes	CY 2017	CY 2018	Target Performance
Breast Biopsy (969 valid episodes)*			
1. Appropriate Diagnostic Workup Rate (≥ 90%)	82.8%	80.8%	1
2. Core Needle Biopsy Rate (≥ 85%)**	77.5%	82.2%	1
Tonsillectomy (6,264 valid episodes)			
1. Bleeding Up to Two Days Following the Procedure (≤ 10%)	0.7%	0.5%	1
Otitis Media (137,276 valid episodes)			
1. Otitis Media with Effusion (OME) Episodes without Antibiotics Filled (≥ 25%)**	27.7%	26.2%	†
2. Non-OME Episodes with Amoxicillin (≥ 60%)**	64.3%	66.9%	1



^{*}Valid episodes in 2018 performance period across all three MCOs

^{**} This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes.

Wave 6 Episodes	CY 2017	CY 2018	Target Performance
Skin and Soft Tissue Infection (47,286 valid episode			
 Bacterial Cultures when Incision and Drainage Performed (≥ 50%)** 	42.4%	42.5%	Ť
2. SSTI Episodes with a First Line Antibiotic (≥ 85%)**	97.7%	97.8%	†
HIV (1,898 valid episodes)			
1. Periodic anti-retroviral therapy (ART) refill (≥ 85%)	71.6%	73.1%	1
Diabetes Acute Exacerbation (891 valid episodes)			
 Follow-up care in the first 14 days of the post- trigger window (≥ 30%) 	25.4%	30.6%	†
Pancreatitis (707 valid episodes)			
1. Follow-up care in the first 14 days of the post-trigger window (≥ 35%)	31.9%	35.8%	1

^{**}This gain sharing quality metric applies to a subpopulation. As a result, the rate is not indicative of performance for all valid episodes.



^{*}Valid episodes in 2018 performance period across all three MCOs